Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

166 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-15

Study Completion Date

2024-06-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Influenza and other acute respiratory viral infections remain practically uncontrollable diseases due to the high variability of the antigenic structure of influenza viruses and the heterogeneity of pathogens of acute respiratory infections. Therefore, for the prevention and treatment of influenza, acute respiratory viral infections and herpes infections, it is relevant to develop drugs - immunomodulators that mobilize the reserves of nonspecific and specific immune systems and enhance the effects of these systems against the pathogens. The drug CYCLOFERON, 150 mg, enteric-coated tablets, contains the active substance meglumine acridone acetate, which is an interferon inducer. Interferons are the most important system of innate immunity, which has antiviral and immunomodulatory effects, and can protect the body from infection with a virus, and in case of infection, fight the causative agent of the disease. The planned clinical trial of the efficacy and safety of the drug CYCLOFERON in the dosage form of a tablet will study its ability to prevent influenza and other respiratory viral infections in adults who have already had close contact with patients with manifest disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparative Clinical Trial of Efficacy and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza

NCT01850446

Influenza

COMPLETED PHASE4

ADC189 Tablets on Influenza A Virus Infection/Influenza B Virus Infection

NCT06342921

Safety Issues Effect of Drug

COMPLETED PHASE2/PHASE3

Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza

NCT01804946

Influenza

COMPLETED PHASE4

Safety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults

NCT00793000

Respiratory Tract Infections

COMPLETED PHASE1

Evaluation the Safety and Tolerance of GP681 Tablets in Healthy Subjects

NCT04729764

Influenza

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza Acute Respiratory Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Double-blind, placebo-controlled, randomized, two-parallel group comparative study

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Randomization is performed using the Internet Interactive Response System (IWRS) before the start of the drug dosing period. During the randomization procedure, the investigator, after assessing whether the subject meets the inclusion criteria and the absence of non-inclusion criteria, will contact IWRS, the system will record the fact that the subject has been randomized and will automatically report the package number of the drug that must be given to the subject.

The study drug CYCLOFERON®, enteric-coated tablets, 150 mg (NTFF POLYSAN LLC, Russia), is supplied in the form of enteric-coated tablets, 150 mg. 10 tablets in a blister pack, 5 blister packs in a cardboard box.

The reference drug PLACEBO, enteric-coated tablets, 150 mg (NTFF POLYSAN LLC, Russia), is supplied in the form of enteric-coated tablets, 150 mg. 10 tablets in a blister pack, 5 blister packs in a cardboard box.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cycloferon

Intake of Cycloferon, enteric-coated tablets, 150 mg, 4 tablets (600 mg) per day on days 1, 2, 4, 6 and 8.

Group Type EXPERIMENTAL

Cycloferon

Intervention Type DRUG

Cycloferon, enteric-coated tablets, 150 mg, 4 tablets (600 mg) per day on days 1, 2, 4, 6 and 8.

Placebo

Intake of Placebo, 4 tablets per day, on days 1, 2, 4, 6 and 8.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo tablets, 4 tablets per day on days 1, 2, 4, 6 and 8

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cycloferon

Cycloferon, enteric-coated tablets, 150 mg, 4 tablets (600 mg) per day on days 1, 2, 4, 6 and 8.

Intervention Type DRUG

Placebo

Placebo tablets, 4 tablets per day on days 1, 2, 4, 6 and 8

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Meglumine acridоnacetate

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female subjects aged 18 to 65 years inclusive.
2. Written informed consent.
3. Co-living with persons who has developed influenza or other acute respiratory viral infection, diagnosed no more than 3 days ago.
4. No signs of acute respiratory viral infection, influenza or COVID-19 at the time of inclusion in the study.
5. For women with preserved reproductive potential - a negative pregnancy test and consent to use approved methods of contraception during the entire period of participation in the study; for men - consent to use approved methods of contraception during the entire period of participation in the study and for 3 weeks after the end of the study.

Exclusion Criteria

1. Known or suspected hypersensitivity to meglumine acridone acetate and/or any other component of the drug/placebo.
2. Lactose intolerance
3. Diseases of the digestive system in the acute stage (erosions, gastric and/or duodenal ulcers, gastritis and duodenitis).
4. History of allergic reactions.
5. Decompensated liver cirrhosis.
6. Diseases of the thyroid gland.
7. Congenital or acquired immunodeficiency.
8. Signs of acute respiratory viral infection, influenza or COVID-19 at the time of inclusion.
9. Positive result of a rapid test for the presence of SARS-CoV-2 at the time of screening.
10. Vaccination to prevent COVID-19 and/or influenza within 6 months before screening, planned vaccination during a clinical trial.
11. History of positive test result for HIV types 1 or 2.
12. Pregnancy or breastfeeding period (for women).
13. Alcoholism, drug addiction, substance and/or drug abuse in history and/or at the time of screening.
14. Participation in another clinical trial within 3 months before inclusion.
15. Subject is already receiving cycloferon.
16. Subject is receiving prohibited therapy or was receiving it within 30 days prior to screening.
17. Failure to observe the subject during the study period.
18. Other reasons that, in the opinion of the researcher, prevent the subject from participating in the study or create an unreasonable risk (for example, a history of autoimmune diseases, etc.).

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No